IJSR International Journal of Scientific Research 2277 - 8179 Indian Society for Health and Advanced Research ijsr-8-3-18420 Original Research Paper HEMATOLOGICAL AND COAGULATION ABNORMALITIES IN CIRRHOTICS WITH DECOMPENSATION RAVITEJA CHERUKURI Dr. March 2019 8 3 01 02 ABSTRACT

BACKGROUND: Decompensated cirrhosis is cirrhosis characterised by the development of jaundice, ascites, variceal haemorrhage, or hepatic encephalopathy. Liver diseases can manifest with a number of systemic symptoms like circulatory changes, endocrinopathy, renal dysfunction, electrolyte disturbances and haematological abnormalities. Haematological abnormalities add to significant morbidity and mortality in chronic liver disease. Hence, the present study was undertaken to estimate the various haematological abnormalities in decompensated cirrhosis. METHODOLOGY: The present Cross sectional observational study ”Haematological and coagulation abnormalities in decompensated cirrhosis” was carried out in the Department of General Medicine, GSL Medical College and General Hospital, Rajahmundry from OCTOBER 1st–2016 to MARCH 30th–2018. A total of 130 patients were observed after following the inclusion and exclusion criteria. RESULTS: The mean age was 55.66 years. The study population constituted 10.8% females and 89.2% males. The most common form of decompensation was ascites in 123 cases (94.6%). Commonest etiology was alcohol abuse in 89 (68.4%). Mean hb% of the study population was 8.97 ± 2.21 g/dl. Normocytic normochromic anemia was commonly observed. 22 cases (16.9%) had leukopenia and 24 cases (18.5%) had leucocytosis. 91 cases (70%) had thrombocytopenia. PT was prolonged in 93 cases (71.5%) and aPTT was prolonged in 60 (46.2%) cases. CONCLUSION: Haematological and haemostatic abnormalities are very common in decompensated cirrhosis. Hence all the cirrhosis patients must be evaluated for haematological and haemostatic abnormalities and should be monitored for the development of complications. Early anticipation, detection and appropriate treatment can prevent significant morbidity and mortality associated with cirrhosis